Citrate Anticoagulation in Renal Replacement Therapy: Impact of a High Post-filter Calcium Target on Efficacy

Phase

Condition

Renal Failure

Kidney Disease

Kidney Failure

Treatment

Citrate

Clinical Study ID

NCT05814341

APHP220257

2022-003678-22

Ages > 18
All Genders

Study Summary

Regional citrate anticoagulation (RCA) is the recommended method for anticoagulation in continuous renal replacement therapy (CRRT). However, the optimal post-filter ionized calcium (iCa) target level remains unclear. Currently, it is titrated to a post-filter iCa target ranging from 0.25 to 0.35 mmol/L, which is derived from a few underpowered trials. There are potential side effects associated with citrate administration, which may be increased in patient with liver failure and/or tissue dysoxia, such as alkalemia, acidemia, hypernatremia, hypocalcemia, hypomagnesemia, and citrate accumulation. Consequently, citrate anticoagulation is contraindicated in the most severe cases. The challenge is to use the minimum necessary dose of citrate to ensure both effective anticoagulation of the circuit and limit citrate administration to reduce the risks of metabolic complications and accumulation. This approach expands the indications for citrate, standardizes practice, and reduces financial costs. Investigators hypothesized that increasing the post-filter iCa target in RCA can limit the dose of citrate, thereby avoiding adverse effects (safety) without compromising the effectiveness of the treatment in preventing filter clotting. The aim of this study is to evaluate the impact of an increased post-filter iCa target from 0.25-0.35 to 0.35-0.45 mmol/L on the incidence of filter clotting for RCA-CRRT in critically ill patients. Investigators are designing a multicenter randomized controlled non-inferiority study.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Age ≥ 18 years old
Hospitalized in intensive care and presenting an indication for extra renalreplacement therapy with Regional citrate anticoagulation (RCA)
Patients covered by social security regimen (excepting AME)
Having given their written consent or, if the patient is unable to consent and isaccompanied, written consent from or legal representative or the close relative. Ifthe patient is unable to consent and is not accompanied, due to the urgency of theprocedure, the patient can also be included on the decision of the investigator (inclusion procedure in an emergency situation with subsequent necessity to sign aconsent to prosecute).

Exclusion

Exclusion Criteria:

Patients receiving curative systemic anticoagulation
Patients with a contraindication to the use of citrate : - Hypersensitivity toRegiocit®
Patients with a contraindication to the administration of the ancillary drugsPhoxilium® and calcium chloride
Patients with an absolute contraindication to the use of citrate due to a lack ofmetabolism in the Krebs cycle and therefore a major risk of accumulation:

Severe impairment of liver function with PT < 30% and lactates > 3mmol/l
Severe tissue dysoxia in uncontrolled shock with lactic acidosis (lactates > 4mmol/l)
Drug toxicity (metformin, paracetamol, propofol, cyclosporine)

Pregnant woman
People under legal protection measure (guardianship or safeguard measures)
A patient legal representative or the close relative who declined to participate
Patient deprived of liberty by a judicial or administrative decision
Patient participating to another interventional study that may have an impact on theevaluation criteria of this study -

Study Design

Citrate

July 01, 2023

December 15, 2024

Study Description

RCA-CRRT will be ordered based on clinical indications and will be performed according to a standardized protocol (available as online supplementary material) in continuous veno-venous hemofiltration mode with the same system (Prismaflex®; Gambro-Baxter, Deerfield, IL, USA) and a 0.9 m2 high-flux AN69 membrane. Blood flow will be maintained between 120 and 180 mL/min according to the patient's ideal body weight. The prescribed dose of filtration will be 30 mL/kg/h to achieve a delivered dose of 20-25 mL/kg/h, following KDIGO guidelines. A citrated replacement solution (Regiocit®; Gambro-Baxter), containing 18.0 mmol/L of citrate, will be delivered continuously to the blood before the filter of the extracorporeal circuit. The rate of infusion of predilution replacement flow will be coupled to the blood flow, aiming for a stable citrate concentration in the extracorporeal circuit. The initial citrate dose will be 3.0 mmol/L of blood, and then citrate flow rate will be adjusted to the post-filter iCa target according to the protocol. Post-filter iCa will be measured on ABL90 FLEX PLUS™ (Radiometer Medical©, Copenhagen, Denmark) blood gas analyzer 15 minutes after any change in dose and then every 6 hours. Calcium chloride will be administered to the patient through a central line to maintain systemic-iCa within 1.00-1.30 mmol/L. Fluid removal rates will be left to the discretion of the attending physician in order to achieve optimal fluid balance. Additionally, metabolic monitoring will be carried out by a blood ionogram every 12 hours. The quantitative parameters will be presented as median and interquartile range [IQR], and comparisons will be made using either Student's t-test or the Mann-Whitney U test depending on whether the assumptions of the t-test are met or not. Categorical data will be reported as the number and percentage (%) and will be compared using Fisher's exact or chi-square test, as appropriate. The incidence of filter clotting will be expressed in absolute values (n) and percentage (%). Comparison between groups will be performed using Pearson's Chi-square test. The analysis of the primary endpoint will be conducted on a per-protocol basis as a first intention (the most conservative approach in a non-inferiority study) and on an intention-to-treat basis. Filter lifespan until clotting curves according to the post-filter iCa2 target will be plotted using the Kaplan-Meier method and compared using the log-rank test.

Connect with a study center

Hospital Pitie Salpetriere
Paris, 75013
France
Site Not Available
Hospital Pitie Salpetriere
Paris 2988507, 75013
France
Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.